These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 10861435

  • 1. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.
    Li CI, Weiss NS, Stanford JL, Daling JR.
    Cancer; 2000 Jun 01; 88(11):2570-7. PubMed ID: 10861435
    [Abstract] [Full Text] [Related]

  • 2. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.
    Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R.
    Cancer; 2002 Dec 15; 95(12):2455-64. PubMed ID: 12467057
    [Abstract] [Full Text] [Related]

  • 3. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
    Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR.
    JAMA; 2003 Jun 25; 289(24):3254-63. PubMed ID: 12824206
    [Abstract] [Full Text] [Related]

  • 4. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
    Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE.
    Breast Cancer Res Treat; 2014 Jun 25; 145(2):481-9. PubMed ID: 24748570
    [Abstract] [Full Text] [Related]

  • 5. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.
    Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW.
    Breast Cancer Res; 2006 Jun 25; 8(1):R11. PubMed ID: 16507159
    [Abstract] [Full Text] [Related]

  • 6. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.
    Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR.
    Cancer Epidemiol Biomarkers Prev; 2008 Jan 25; 17(1):43-50. PubMed ID: 18199710
    [Abstract] [Full Text] [Related]

  • 7. Trends in incidence rates of invasive lobular and ductal breast carcinoma.
    Li CI, Anderson BO, Daling JR, Moe RE.
    JAMA; 2003 Mar 19; 289(11):1421-4. PubMed ID: 12636465
    [Abstract] [Full Text] [Related]

  • 8. Menopausal hormone therapy and risk of clinical breast cancer subtypes.
    Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D.
    Cancer Epidemiol Biomarkers Prev; 2009 Apr 19; 18(4):1188-96. PubMed ID: 19336542
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA.
    JAMA; 1995 Jul 12; 274(2):137-42. PubMed ID: 7596001
    [Abstract] [Full Text] [Related]

  • 11. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer.
    Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Strom BL, Simon MS, Press MF, McDonald JA, Ursin G, Burkman RT, Deapen D, Spirtas R.
    Cancer Epidemiol Biomarkers Prev; 2006 May 12; 15(5):946-54. PubMed ID: 16702375
    [Abstract] [Full Text] [Related]

  • 12. Hormone replacement therapy in relation to breast cancer.
    Chen CL, Weiss NS, Newcomb P, Barlow W, White E.
    JAMA; 2002 Feb 13; 287(6):734-41. PubMed ID: 11851540
    [Abstract] [Full Text] [Related]

  • 13. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study.
    Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L.
    Cancer; 2004 Jun 01; 100(11):2328-37. PubMed ID: 15160335
    [Abstract] [Full Text] [Related]

  • 14. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype.
    Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C.
    Cancer; 2009 Mar 01; 115(5):936-45. PubMed ID: 19156895
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
    Kjartansdottir OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, Ursin G, Tryggvadottir L.
    Breast Cancer Res Treat; 2017 Jun 01; 163(2):363-373. PubMed ID: 28281022
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States).
    Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA, Daling JR.
    Cancer Causes Control; 2003 Apr 01; 14(3):225-33. PubMed ID: 12814201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.